Estrogen receptor ␣ (ER␣) is a major transducer of estrogenmediated physiological signals. ER␣ is a member of the nuclear receptor superfamily, which encompasses ligand-dependent transcription factors. The C terminus of nuclear receptors, termed the F domain, is the least homologous region among the members of this family. The ER␣ F domain possesses 45 amino acids; however, its function remains unclear. We noticed that the homology of the F domains between mouse and human ER␣s is remarkably lower (75.6% similarity) than that between the entire proteins (94.7% similarity). To assess the functionality of the ER␣ F domains, here we generated chimeric ER␣ expression constructs with mouse-human-exchanged F domains. Using cell-based in vitro assays, we analyzed the transcriptional coactivator interaction and ligand-binding domain dimerization activities of these mouse-human F domain-swapped ER␣s. We found that the transcriptional activity of the mouse WT ER␣ is more potent than that of the human WT ER␣ in the human hepatoma cell line HepG2. 4-Hydroxytamoxifen (4OHT)-mediated transcriptional activity of mouse-human F domain-swapped ER␣s was the inverse of the WT ER␣ activities but not estradiol-mediated transcriptional activities. Further experiments with constructs containing deletion or point mutations of a predicted ␤-strand region within the F domain suggested that this region governs the species-specific 4OHT-mediated transcriptional activity of ER␣. We conclude that the ER␣ F domain has a species-specific function in 4OHT-mediated receptor transactivation and that mouse-human F domain-swapped ER␣ mutants enable key insights into ER␣ F domain structure and function.
abolic regulation. Estrogen receptors (ER␣ 3 and ER␤) are ligand-dependent transcription regulators, which transmit estrogen signals to estrogen-mediated physiological functions (1) . The phenotypes of ER-null mutant mice have suggested that ER␣ plays a primary role in a number of estrogen-mediated physiological responses compared with ER␤-null mutant mice (2) . Many of these phenotypes of ER␣ activities are also observed in clinical cases of ER␣ insensitivity (3) (4) (5) . Thus, ER␣ has been a major target for the development of therapeutic reagents, such as selective estrogen receptor modulators (SERM) and selective estrogen receptor degraders that control estrogen-mediated physiological responses.
ER␣ contains highly-conserved domain structures common among the nuclear receptor superfamily, designated A through F domains. The A/B domain, which contains transcription activation function 1 (AF-1), is localized on the N terminus, and the structure varies between the nuclear receptors. In contrast, the C domain, also known as the DNA-binding domain (DBD), and the E domain, also known as the ligand-binding domain (LBD), are highly conserved between nuclear receptors. The E domain contains the ligand-binding pocket and transcription activation function 2 (AF-2). The F domain is localized on the very end of the C termini of some nuclear receptors and is the most variable domain between the family members. Even within orthologues of ER␣, the homology of the F domain sequence is significantly lower than the other domains. For instance, the similarities between human and mouse ER␣ A/B domain, F domain, and the whole protein are 90.6, 75.6, and 94.7%, respectively (Table 1) .
Concerns have arisen over differential pharmacokinetics of estrogenic compounds across different species, which are relevant to the findings of differential activities of estrogenic compounds seen in experimental animal studies (6) . Because of the higher homology of ER␣ protein among species, it has been thought that the differential metabolism of chemicals may be the cause of different estrogenic activities rather than species differences of ER␣ structure. Indeed, the structural difference of ER␣ between animals has also been considered as a contributing factor to the differential estrogenic activities. However, there is limited evidence for differential functionality of ER␣ among different animal species (7) . In addition, it is totally unknown whether the F domain, which is the least homologous region among the species, is involved in the differential functionality of ER␣. The function of human ER␣ F domain has been analyzed by several groups using different experimental models (8 -12) . These reports have suggested that the human ER␣ F domain is needed for the partial agonist activity of 4-hydroxytamoxifen (4OHT) and the efficacy of estradiol (E2)-mediated transcriptional activity of ER␣. However, the mechanism of the precise F domain functionality is still unclear.
The differential estrogenic activity of tamoxifen between humans and mice has been discussed. However, there are still no informative conclusions. We evaluated the transcription activities of human and mouse ER␣ using a cell-based in vitro reporter assay and found differential transcription activities under equivalent conditions in a human hepatoma cell line. To confirm F domain's contribution to this differential activity, we generated chimeric mouse-human F domain-swapped ER␣ expression plasmids. Analyses suggested that the F domain governs the species difference of ER␣ activity, and a specific region of the F domain contributes to the differential functionality for E2-and 4OHT-mediated transcription. Our strategy of exchanging the mouse-human F domains of ER␣ presents new insight into evaluating ER␣ F domain functionality and potentially for explaining differential estrogenic chemical activities among species.
Results

Differential transcriptional activity between mouse and human ER␣ in the human hepatoma cell line
At first, we analyzed the estrogen-responsive element (ERE)-dependent transcriptional activity of mouse ER␣ (mER␣) and human ER␣ (hER␣) using ERE-fused luciferase (luc) reporters (3xERE-TATA-luc and C3-110tk-luc). We chose both a mouse and a human cell line to account for both species; the mouse fibroblast cell line (Balb3T3A31) and the human hepatoma cell line (HepG2) were transfected with the reporter plasmid and the receptor expression plasmid (pcDNA3-mERa or pcDNA3-hERa) or the empty plasmid (pcDNA3). Transactivation levels were expressed as relative activity compared with the level of pcDNA3. The basal activity of mER␣ without ligands was higher than hER␣ in the Balb3T3A31 cells, but there was no difference in the maximum level of E2-mediated transactivation (Fig. 1A) . In the Balb3T3A31 cells, the activity of mER␣ was blocked by 4OHT. However, the activity of hER␣ was not stimulated or blocked by 4OHT (Fig. 1B) . In the HepG2 cells, E2- (Fig. 1, C and E) and 4OHT (Fig. 1, D and F) -mediated transcriptional activity of mER␣ was significantly higher than hER␣. Although the transcriptional activities of mER␣ and hER␣ were different in the HepG2 cells, there was no difference in the receptor protein expression levels (Fig. 1G ).
AF-1 activity was similar between mouse and human ER␣ in the HepG2 cells
To understand the contribution of transactivation function domains (AF-1 and AF-2) in the differential activity of mER␣ and hER␣ in the HepG2 cells, we analyzed AF-1 activities using Figure 1 . Differential transcriptional activity between human and mouse ER␣. Balb3T3A31 cells were cotransfected with the reporter plasmid (3xERE-TATA-luc), reference plasmid (pRL-TK), and expression vectors for full-length human or mouse ER␣ (hER␣WT or mER␣WT) and empty expression plasmid (pcDNA3). Cells were treated with vehicle (0 nM), E2 (A), or 4OHT (B). Treated concentrations are described in the figures. HepG2 cells were cotransfected with the reporter plasmids (3xERE-TATA-luc, C and D; or C3-110tk-luc, E and F), pRL-TK, and expression vectors for full-length ER␣ or empty expression plasmid (pcDNA3). Cells were treated with vehicle (0 nM), E2 (C and E), or 4OHT (D and F). The luciferase activities for each panel are represented as relative activity over pcDNA3 in each concentration. The activity is represented as mean Ϯ S.D. Two-way ANOVA was performed to indicate significant difference: a, between mER␣ and hER␣ activities; b, hER␣ activity against vehicle; c, mER␣ activity against vehicle; p Ͻ 0.05. G, whole-cell lysates extracted from the plasmid-transfected HepG2 cells were analyzed by immunoblotting with anti-ER␣ antibody to demonstrate expression levels of ER␣ WT. ␤-Actin was used as a loading control (Actin). Representative Western blotting is shown.
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the AF-2 truncated ER␣ mutants (mER␣339 and hER␣340) (Fig. 2, A and B) , which exhibit only a constitutive AF-1-mediated transcriptional activity (13, 14) . There was no difference between mER␣339 and hER␣340 in ERE-luc reporter activation function (Fig. 2, C and D) , suggesting that the AF-1 activity of mouse and human ER␣ is indistinguishable in the HepG2 cells.
AF-2 activity was different between mouse and human ER␣ in the HepG2 cells
Next, we evaluated the AF-2 activity of mouse and human ER␣ using the G5-luc reporter and Gal4DBD-fused ER␣ LBDs (pBIND-mEF, pBIND-hEF, pBIND-mE⌬F, and pBIND-hE⌬F). As shown in Fig. 3A , E2-dependent transactivation function of mER␣ AF-2 (pBIND-mEF) was higher than hER␣ AF-2 (pBIND-hEF). The transcriptional activity was reduced by F domain truncation (pBIND-mE⌬F and pBIND-hE⌬F). Furthermore, we analyzed the ligand-dependent coactivator (NCOA) recruitment activity to AF-2 using the mammalian two-hybrid assay. The expression plasmids for the Gal4DBD-fused nuclear receptor interaction domain (RID) of NCOA1, -2, or -3 (pM-SRC1-NR, pM-GRIP1-NR, or pM-ACTR-NR) and the expression plasmids for the VP16AD fused-ER␣ LBDs (pACT-mEF, pACT-hEF, pACT-mE⌬F, or pACT-hE⌬F) were cotransfected with G5-luc reporter in the HepG2 cells. As shown in Fig. 3B , E2-dependent NCOA recruitment activity of mER␣ was higher than hER␣. Furthermore, F domain truncation (pACTmE⌬F or pACT-hE⌬F) reduced the activity of NCOA recruitment. These results were consistent with the E2-dependent activation levels of mouse and human ER␣ AF-2 (Fig. 3A) . Such findings suggest that the E2-mediated differential activities of mER␣ and hER␣ correlate with the differential AF-2 activities of mouse and human ER␣ in HepG2 cells.
F domain contributes to the differential transcriptional activity of mouse and human ER␣
The results of the F domain truncated mutant suggested that the F domain is highly associated with the AF-2 activity of mER␣ and hER␣. To assess the role of the F domain in AF-2 activity, we generated ER␣ mutants that contain mouse-and human-exchanged F domains (Fig. 4, A and B) . HepG2 cells were transfected with an ERE-luc reporter plasmid and the expression plasmid for the F domain-swapped receptor (mER␣-hF and hER␣-mF) or the control receptor (mER␣-mF and hER␣-hF). The E2-mediated activity of F domain-swapped receptors showed in-between levels compared with the levels of control receptors (Fig. 4, C and E) . In response to 4OHT, the activities of mER␣ and hER␣ were totally inverted by F domain swapping (Fig. 4, D and F) . These results suggest that the F domain influences the differential activities of mER␣ and hER␣ to 4OHT. 
Species difference of ER␣ F domain functionality F domain is involved in the E2-dependent coactivator recruitment to the LBD
We assessed the ligand-dependent AF-2 activity of F domain-swapped ER␣ using a G5-luc reporter and Gal4DBD-fused LBDs. The E2-dependent AF-2 activity of mER␣-hF (pBIND-mEhF) was lower than the mER␣-mF (pBINDmEmF). In contrast, the AF-2 activity of hER␣-mF (pBINDhEmF) was higher than the hER␣-hF (pBIND-hEhF) (Fig. 5A , left panel). 4OHT did not activate the G5-luc reporter through any Gal4DBD-fused LBDs (Fig. 5A, right panel) . Furthermore, E2-dependent NCOA recruitment activity of mER␣-hF LBD (pACT-mEhF) was lower than the mER␣-mF LBD (pACTmEmF). In contrast, E2-dependent NCOA recruitment activity of hER␣-mF LBD (pACT-hEmF) was higher than the hER␣-hF LBD (pACT-hEhF) (Fig. 5B) . These results clearly suggest that the F domain modulates the E2-dependent coactivator-interacting surface of ER␣ LBD.
F domain is involved in the 4OHT-dependent LBD dimerization activity
Because we have reported previously that the efficacy of LBD dimerization associates with the partial agonist activity of 4OHT (15), 4OHT-dependent LBD dimerization activity was analyzed by using the mammalian two-hybrid assay. HepG2 cells were cotransfected with the G5-luc reporter and plasmids for expressing Gal4DBD-fused mEmF, mEhF, hEhF, or hEmF (pBIND-EF) and in the presence of plasmids for expressing VP16AD alone (pACT) or VP16AD-fused mEmF, mEhF, hEhF, or hEmF (pACT-EF). Cells were treated with 0.1-10 nM 4OHT or vehicle. Because the 4OHT-mediated dimerization activity of mER␣ LBD was significantly higher than hER␣ LBD, the results are shown separately for mER␣ and hER␣ (Fig. 6, A and B) . 4OHT-mediated dimerization activity of the mER␣ LBD (mEmF) was significantly reduced by the swapping to the human F domain (mEhF) (Fig. 6A ). In contrast, the lower 4OHT-mediated dimerization activity of hER␣ LBD (hEhF) was increased by the swapping and incorporation of the mouse F domain (hEmF) (Fig. 6B ). These results suggest that the 4OHT-mediated dimerization activities of mouse and human ER␣ LBD are governed by the F domain. These results coincide with the 4OHT-mediated ERE-dependent transcriptional activity of F domain-swapped ER␣ mutants (Fig. 4, D  and F) . 
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The functions of possible structural regions of the human ER␣ F domain have been reported, including a predictive ␤-strand in the C terminus of the F domain; however, actual conformation is still uncertain (10, 11) . We analyzed the transcriptional activity of several ER␣ mutants focused on the element near a suggested ␤-strand in the F domain to confirm the functional relevance of this region. Three amino acids (tyrosine-tyrosine-isoleucine, YYI) were deleted from the F domain to disrupt the predicted ␤-strand structure (mER␣⌬YYI and hER␣⌬YYI) (Fig. 7A) . The expression level of mutant receptor protein was lower than WT in both species (Fig. 7B) . Although the protein level was lower than WT, mouse and human ER␣⌬YYI exhibited E2-mediated transcriptional activity similar to WT (Fig.  7C ). Interestingly, 4OHT-mediated transcriptional activity of mER␣⌬YYI was significantly decreased but not hER␣⌬YYI (Fig.  7D) . Furthermore, we generated a mutant hER␣ protein expression plasmid, which replaced the three amino acids on the flanking of YYI to the mouse corresponding residues. The lysine (hER␣581) on the N-terminal flanking of YYI sequence was replaced with threonine and the threonine (hER␣585) and glycine (hER␣586) on the C-terminal flanking of YYI sequence were replaced with prolines (hER␣K581T,T585P,G586P; denoted as hER␣TyyiPP) (Fig.  7E) . The E2-mediated transcriptional activity of hER␣TyyiPP was identical to hER␣-hF (Fig. 7F ). In contrast, 4OHT-mediated transcriptional activity of hER␣TyyiPP was significantly higher than hER␣-hF and similar to mER␣-mF (Fig. 7G) . Furthermore, we analyzed the LBD dimerization activity of K581T,T585P,G586P-mutated human ER␣ (hEF-TyyiPP) using the mammalian twohybrid assay. 4OHT-mediated dimerization activity of hEF-TyyiPP was significantly higher than WT human ER␣ LBD (hEF) (Fig.  7H) . These results suggest that the mouse-specific residues around the predictive ␤-strand in the F domain are involved in the differential activities of 4OHT-mediated mER␣ and hER␣ transcriptional regulation. Figure 6 . F domain is involved in the 4OHT-dependent LBD dimerization. A, HepG2 cells were cotransfected with pG5-luc and expression vector for Gal4DBD-fused mER␣ LBD in the presence of expression vector for VP16AD (pB-mEmFϩpA or pB-mEhFϩpA) or VP16AD-fused mER␣ LBD (pB-mEmFϩpA-mEmF or pB-mEhFϩpA-mEhF). Cells were treated with either vehicle (0 nM) or 4OHT (0.1-10 nM). The luciferase activity is represented as relative activity that is set as 1 in the vehicle (0 nM)-treated pB-mEmFϩpA-or pB-mEhFϩpA-transfected cells for pB-mEmFϩpA-mEmF or pB-mEhFϩpA-mEhF, respectively. The activity is represented as mean Ϯ S.D. Two-way ANOVA was performed to indicate significant difference: a, mEmF dimerization activity against vehicle (0 nM); b, mEhF dimerization activity against vehicle (0 nM); c, between mEmF dimerization and mEhF dimerization activities in each concentration; p Ͻ 0.05. B, HepG2 cells were cotransfected with pG5-luc and expression vector for Gal4DBD-fused hER␣ LBD in the presence of expression vector for VP16AD (pB-hEhFϩpA or pB-hEmFϩpA) or VP16AD-fused hER␣ LBD (pB-hEhFϩpA-hEhF or pB-hEmFϩpA-hEmF). Cells were treated with either vehicle (0 nM) or 4OHT (0.1-10 nM). The luciferase activity is represented as relative activity that is set as 1 in the vehicle (0 nM)-treated pB-hEhFϩpA-or pB-hEmFϩpA-transfected cells for pB-hEhFϩpA-hEhF or pB-hEmFϩpA-hEmF, respectively. The activity is represented as mean Ϯ S.D. Two-way ANOVA was performed to indicate significant difference: a, hEhF dimerization activity against vehicle (0 nM); b, hEmF dimerization activity against vehicle (0 nM); c, between hEhF dimerization and hEmF dimerization activities in each concentration; p Ͻ 0.05. 
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Mouse ER␣ is more potent than human ER␣ for estrogen-responsive gene activation Finally, we examined the efficacy of E2-or 4OHT-mediated endogenous gene activation through mouse and human ER␣ by using mER␣-or hER␣-transfected HeLa cells (Fig. 8) . Total RNA was extracted from the cells that were treated with 10 nM E2 or 4OHT for 24 h. As examples, the expression levels of SERPINB9 (also known as PI9) and TFF1 (also known as pS2) genes were analyzed. These genes are known estrogen-responsive genes in several cell lines (16 -19) . The mRNA level of ER␣-regulated genes was normalized by the transcript of neomycin-resistant gene (Neo), which is expressed from the pcDNA3 plasmid for normalizing the transfection efficiency. SERPINB9 and TFF1 genes were activated by E2 in an ER␣-dependent manner (Fig. 8, A and C) . E2-induced mRNA levels of both genes were slightly higher in the mER␣-transfected cells than the hER␣-transfected cells. SERPINB9 gene was activated by 4OHT in an ER␣-dependent manner (Fig. 8B ), but the TFF1 gene was not activated by 4OHT (Fig. 8D) . Importantly, the 4OHT-induced SERPINB9 mRNA level was significantly higher in the mER␣-transfected cells than hER␣-transfected cells (Fig. 8B) , which is consistent with the in vitro observations in this report.
Discussion
The differential estrogenic activity of tamoxifen in experimental animals has been reported (6). These findings, led to a question of the differential estrogenic activity of tamoxifen between the human and mouse species. However, the conclusion to explain these differential activities is still unclear. In particular, there are no findings associating the structural difference between human and mouse ER␣ with the differential estrogenic activity of tamoxifen. The high homology between human and mouse ER␣ (94.7% similarity) has led to the thought 
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that the function of these receptors is identical. However, we found that the efficacy of transcriptional activity of mER␣ is more potent than hER␣. Specifically, the results of F domainswapped ER␣ mutants suggested that the F domain contributes to the tamoxifen-mediated differential transcriptional activity of mER␣ and hER␣.
Our results suggested that the N-terminal transactivation function (AF-1) is the primary element for the 4OHT-dependent transcriptional activity of full-length ER␣, following the previous reports (13, 14) , and that the F domain plays a role in this regulation. We have previously reported that the SERMmediated partial agonist activity of ER␣ is correlated with the efficacy of LBD (EF domain) dimerization cooperating with ERE binding (15) . As we demonstrate in this report, 4OHT-dependent dimerization of mouse ER␣ LBD is more potent than human ER␣ LBD, which is consistent with the 4OHT-dependent full-length ER␣ transcriptional activities. The species difference of 4OHT-mediated LBD dimerization efficiency was totally changed by the F domain swapping and that level reflects the full-length mutant ER␣ transcriptional activities. These results clearly suggest that the F domain structure is contributing to an important role in 4OHT-dependent LBD dimerization and partial agonist activity of ER␣.
As we showed here, the SERPINB9 gene was activated by 4OHT in the ER␣-transfected HeLa cells but not TFF1. This observation agrees with the promoter context-dependent tamoxifen activity as reported previously (13) . 4OHT-dependent SERPINB9 gene expression was higher in the mER␣-than hER␣-transfected cells, suggesting that the agonist activity of 4OHT through mER␣ was more potent than hER␣ in the same promoter context. 4OHT activity via mER␣ was higher than hER␣ with each of the different promoters that we analyzed (3xERE-TATA, C3-110tk, and SERPINB9). This may suggest that the species differences of 4OHT-mediated ER␣ activity is independent of the promoter context. In other words, structural differences between human and mouse ER␣ could cause the species differences of agonist activity of 4OHT.
F domain replacement did not affect E2-mediated full-length ER␣ transactivation strikingly, which was different from 4OHT-mediated regulation. However, the efficacy of E2-mediated NCOA interaction to the AF-2 was reversed by F domain swapping, and it was consistent with the E2-dependent AF-2 activity of F domain-swapped ER␣ mutants. These results suggest that the F domain contributes to the modulation of the E2-dependent coactivator interacting surface of LBD, but it provides a limited contribution to the E2-dependent full-length ER␣ transactivation. The differential activities of F domainswapped ER␣ on the C3-110tk and 3xERE-TATA reporters imply that the E2-activated full-length ER␣ is functioning in a different manner on each responsive element. To verify this hypothesis, we performed further analysis using the reporters that contain 1-3 consensus ERE motifs fused with a thymidine kinase (tk) promoter (Fig. 9) . E2-mediated full-length mouse ER␣ transcriptional activity was higher than human ER␣ for those reporters in HepG2 cells. Interestingly, the profile of the transcriptional activities of F domain-swapped ER␣ mutants for 1xERE-tk reporter was similar to the profile of C3-110tk reporter; the profiles of 2xERE-tk and 3xERE-tk reporters were similar to 3xERE-TATA-luc. Importantly, the sole activity of AF-1 and AF-2 was not observed on the 1xERE-tk reporter, contrasting with the activities on 2xERE-tk and 3xERE-tk reporters. These results suggested that the monomeric or multimeric binding of the E2-mediated ER␣ dimer on the ERE regulates transcriptional activity in a different manner. Therefore, the AF-2 (transactivation function of EF domain) works with AF-1 synergistically when ER␣ is bound on a single ERE. When ER␣ proteins bind on multiple EREs, AF-1 and AF-2 work for E2-mediated transactivation in an additive manner. The characteristics of the F domain may be emphasized when ER␣ dimer is monomerically bound on the ERE.
Schwartz et al. (10) have suggested that the residues of QKYYIT (hER␣ 580 -585) in the human ER␣ F domain contribute to a possible ␤-strand structure. However, the function of this specific region is not well known. The computational prediction analysis for the protein secondary structure suggested that a ␤-strand is likely to exist in this region of mouse ER␣ F domain similar to human ER␣. The results of the YYI sequence-deleted mutant ER␣ suggested that this region is strongly correlated with the species difference of 4OHT-mediated ER␣ transcriptional activity. We recognized that the flanking amino acids of YYI are varied between species; lysine, which is a 5Ј-flanking residue, is highly conserved among primates, but most other mammals have threonine (Thr). The 3Ј-flanking residues, Thr and glycine (Gly) are conserved among mammals except rodents; rodents have prolines instead of Thr and Gly. Further analyses using a human ER␣ mutant with the threepoint mutation swapped to the mouse ER␣ residues in the predicted ␤-strand region (hER␣TyyiPP) suggested that the characteristics of the amino acids flanking the YYI residues are important for the species-specific 4OHT-mediated transactivation function of ER␣. Our strategy of exchanging the mouse-human F domain sequence may be useful to examine the structural features of the ER␣ F domain, because there is no published crystallographic structure of the F domain. However, our study demonstrates a functional difference.
Previous reports using the yeast two-hybrid assay have suggested that the truncation of F domain enhances or does not affect the E2-mediated SRC1 (NCOA1) RID interaction to the human ER␣ LBD (11, 12) . Those results are inconsistent with the transcriptional activity of the F domain truncated ER␣ in mammalian cells (8, 11) . We showed that the truncation of the F domain clearly reduced E2-mediated NCOA RID interaction and AF-2 activity of mouse and human ER␣ in HepG2 cells. Our results suggested that the F domain facilitates the E2-mediated NCOA interaction to the AF-2 surface rather than preventing interaction. The contradiction between our results and previous reports, which used a yeast system, suggests that the function of the F domain is cell type-dependent. We showed here the differential activity of hER␣ and mER␣ in HepG2 cells (human hepatoma cell). We observed the same trends of ER␣-dependent gene regulation in a human cervical cancer cell line, HeLa cells. Thus far, only the mouse fibroblast cell line, Balb3T3A31 cells, showed different results in our analyzed cell types. These results imply that species-specific factor(s) may exist for modulating the F domain function.
In summary, we revealed that the species-specific amino acids of the predicted ␤-strand region on the C terminus of the ER␣ F domain govern the species-dependent tamoxifen-mediated transcriptional activity. Our results also suggest that considerations should be made when analyzing SERM activity in mouse versus human samples because of the existence of differential F domain functionality between human and mouse ER␣.
Experimental procedures
Plasmid constructions
The following plasmids were used for WT and C-terminal end truncated ER␣ protein expression: for pcDNA3-mERa, the plasmid contains full-length (1-599) mouse ER␣; for pcDNA3-mERa339, the plasmid contains 1-339 amino acids (AA) of mouse ER␣ with extension of 10 extra AA (GPYSIVSPKC) in the C terminus derived from the pcDNA3 sequence. pcDNA3-hERa, the plasmid contains full-length (1-595) human ER␣; pcDNA3-hERa340, the plasmid contains 1-340 AA of human ER␣ with extension of 7 extra AA (CMPAGRI) in the C terminus derived from pcDNA3 sequence. The following plasmids were used for N-terminal end truncated ER␣ protein expression: for pcDNA3-121-mERa, the plasmid contains 121-599 AA of mouse ER␣ with an extra MTM sequence in the N terminus; for pcDNA3-117-hERa, the plasmid contains 117-595 AA of human ER␣ with an extra MTM sequence in the N terminus. To generate 
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human-mouse F domain-swapped ER␣ expression plasmids, the control plasmids (mouse and human ER␣ expression plasmids that have an extra BamHI site between the E and F domains) were created by PCR-based site-directed mutagenesis, and the following oligo DNAs were used for the mutagenesis: hERa_1657BamHI_S, 5Ј-CCG CCT ACA TGC GCC CGG ATC CCG TGG AGG GGC ATC C-3Ј, and hERa_1657BamHI_AS, 5Ј-GGA TGC CCC TCC ACG GGA TCC GGG CGC ATG TAG GCG G-3Ј for human ER␣; mERa_1669BamHI_S, 5Ј-CCG CCT TCA TGC CCC AGG ATC CCG CAT GGG AGT GCC CCC-3Ј, and mERa_ 1669BamHI_AS, 5Ј-GGG GGC ACT CCC ATG CGG GAT CCT GGG GCA TGA AGG CGG-3Ј for mouse ER␣. The reaction mixture contains the Pfu Turbo DNA polymerase (Agilent Technologies), a pair of sense (S) and antisense (AS) oligo DNAs, and the plasmid pGEM3zf-hERa_XbaI (the XbaI fragment from pcDNA3-hERa was subcloned into the XbaI site of pGEM3zf vector) or pBluescript-mERaWT_XhoI (the XhoI fragment from pcDNA3-mERa was subcloned into the XhoI site of pBluescript II SK vector) as a template. PCR was performed following the manufacturer's instructions (Agilent Technologies). Mutated clone was confirmed by sequencing (Genewiz). The XbaI fragment from pGEM3zf-hERa_ XbaI1657BamHI was subcloned into the XbaI site of pcDNA3-hERa and then generated pcDNA3-hERa1657BamHI (pcDNA3-hERa-hF); the XhoI fragment from pBluescriptmERaWT_XhoI1669BamHI was subcloned into the XhoI site of pcDNA3-mERa and then generated pcDNA3-mERa1669BamHI (pcDNA3-mERa-mF); the direction of the inserted fragment was determined by NotI digestion. The pcDNA3-mERa-mF plasmid expresses A557G mutant mER␣, and the pcDNA3-hERa-hF plasmid expresses T553G mutant hER␣. The function of mER␣-mF and hER␣-hF for the liganddependent transcriptional activity was identical to mER␣WT and hER␣WT respectively (Fig. S1 ). To generate pcDNA3-mERa-hF and pcDNA3-hERa-mF plasmids, the BamHI fragments from pcDNA3-mERa-mF and pcDNA3-hERa-hF were subcloned into the BamHI site of pcDNA3-hERa and pcDNA3-mERa, respectively. The direction of the inserted fragment was determined by NotI digestion. The plasmids pcDNA3-mERa⌬YYI and pcDNA3-hERa⌬YYI were created by PCR-based site-directed mutagenesis, and the following oligo DNAs were used for the mutagenesis: hERa_Del_YYI_S, 5Ј-CAT CGC ATT CCT TGC AAA AGA CGG GGG AGG CAG-3Ј, and hERa_Del_YYI_AS, 5Ј-CTG CCT CCC CCG TCT TTT GCA AGG AAT GCG ATG-3Ј for human ER␣; del586 -588_S, 5Ј-ACA TTC CTT ACA AAC CCC CCC GGA AGC AGA GG-3Ј, and del586 -588_AS, 5Ј-CCT CTG CTT CCG GGG GGG TTT GTA AGG AAT GT-3Ј for mouse ER␣. pGEM3zf-hERa_XbaI and pBluescript-mERaWT_XhoI were used for a template, respectively. The XbaI fragment from pGEM3zf-hERa⌬YYI was subcloned into the XbaI site of pcDNA3-hERa and then generated pcDNA3-hERa⌬YYI; the XhoI fragment from pBluescript-mERa⌬YYI was subcloned into the XhoI site of pcDNA3-mERa then generated pcDNA3-mERa⌬YYI. The expression plasmid for hER␣K581T, T585P,G586P (pcDNA3-hERaTyyiPP) was created by PCRbased site-directed mutagenesis. The following oligo DNAs were used for the first mutagenesis: hERa_T585P-G586P_S, 5Ј-GAA ACC CTC TGC CTC CGG CGG GAT GTA ATA CTT TTG CAA GGA A-3Ј, and hERa_T585P-G586P_AS, 5Ј-TTC CTT GCA AAA GTA TTA CAT CCC GCC GGA GGC AGA GGG TTT C-3Ј. pGEM3zf-hERa_XbaI was used for a template to generate pGEM3zf-hERaPP_XbaI. The following oligo DNAs were used for the second mutagenesis: hERa-PP_K581T_S, 5Ј-CCG GCG GGA TGT AAT ACG TTT GCA AGG AAT GCG AT-3Ј, and hERa-PP_K581T_AS, 5Ј-ATC GCA TTC CTT GCA AAC GTA TTA CAT CCC GCC GG-3Ј. pGEM3zf-hERaPP_XbaI was used for a template. The XbaI fragment from pGEM3zf-hERaTyyiPP_XbaI was subcloned into the XbaI site of pcDNA3-hERa and then generated pcDNA3-hERaTyyiPP. The pGL3-Basic-TATA-Int-Luc reporter plasmid (3xERE-TATA-luc) (15) and the TK-C3ER1ϩ2 reporter plasmid (C3-110tk-luc) containing the luciferase reporter gene fused with the tk promoter and the minimum estrogen-responsive element (117 bp) of human complement 3 (C3) gene (20) were used for reporter assay. The reporter plasmids 1xERE-TK-luc, 2xERE-TK-luc, and 3xERE-TK-luc were used for reporter assay in Fig. 9 (gift from Dr. McDonnell, Duke University). The plasmid pRL-TK Renilla luciferase expression plasmid (Promega) was used for internal control. Plasmids used for mammalian two-hybrid assay are as follows: the plasmids pM-SRC1-NR, which contains 621-766 AA of human NCOA1; pM-GRIP1-NR, which contains 629 -761 AA of mouse NCOA2; pM-ACTR-NR, which contains 611-784 AA of human NCOA3 (gift from Dr. McDonnell, Duke University) (21), pBIND-mEF, pBIND-mE⌬F (15), pBIND-hEF, pBINDhE⌬F, pBIND-mEmF, pBIND-hEhF, pBIND-mEhF, pBINDhEmF, pBIND-hEF-TyyiPP, and pBIND (Promega) were used for the bait; the plasmids pACT-mEF, pACT-mE⌬F (15), pACT-hEF, pACT-hE⌬F, pACT-mEmF, pACT-hEhF, pACTmEhF, pACT-hEmF, pACT-hEF-TyyiPP, and pACT (Promega) were used for the prey; the plasmid pG5-Luc (Promega) was used for GAL4-binding element-fused reporter gene. The ER␣ EF domain-fused pACT and pBIND plasmids were generated as follows: the template DNAs pcDNA3-hERa-hF, pcDNA3-hERa-TyyiPP, pcDNA3-hERa-mF, and pcDNA3-mERa-mF were amplified by PCR using the following primer sets: hERa-LBD5Ј_SalI: 5Ј-GBTC GAC GCT CTA AGA AGA ACA GCC TGG CCT TGT CCC T-3Ј, and hERa-LBD3Ј_NotI: 5Ј-GCG GCC GCT CTC AGA CTG TGG CAG GGA AAC CCT CTG CC-3Ј (hEhF and hEF-TyyiPP); primers hERaLBD5Ј_SalI and mE/F-3Ј_KpnI: 5Ј-GGT ACC TGG GAG CTC TCA GAT CGT GTT GGG-3Ј (hEmF); primers mE/F5Ј_BamHI: 5Ј-GGA TCC AGC ACA CTA AGA AGA ATA GCC CTG CCT T-3Ј and mE/F-3Ј_KpnI (mEmF). The hER␣ E⌬F-fused pACT and pBIND plasmids were generated as follows: the template DNA pcDNA3-hERa was amplified by PCR using the following primer sets: hERa-LBD5Ј_SalI and hERaLBD3Ј⌬F_NotI: 5Ј-GCG GCC GCG GTG GGC GTC CAG CAT CTC CAG CAG CAG-3Ј. The amplified fragment was cloned into pCR2.1 by TA-cloning kit and sequenced. The inserted fragment was excised by SalI and NotI (hEhF, hE⌬F, and hEF-TyyiPP) or SalI and KpnI (hEmF) and then subcloned into the SalI and NotI or SalI and KpnI sites of pACT or pBIND vectors. To generate the plasmid pACT-mEmF, pACT-mEhF,
pBIND-mEmF, and pBIND-mEhF, the BamHI fragment was excised from the pCR2.1-mEmF and then subcloned into the BamHI site of pACT-hEhF, pACT-hEmF, pBIND-hEhF, and pBIND-hEmF plasmids. The direction of the inserted fragment was determined by NdeI digestion.
Cell culture and transfection condition for luciferase assay
HepG2 cells (human hepatocellular carcinoma) were cultured in phenol red-free ␣-MEM (Invitrogen) supplemented with 10% FBS (Gemini-Bio) and 1% penicillin/streptomycin solution (Sigma). Balb3T3A31 cells (mouse fibroblast) were cultured in phenol red-free ␣-MEM supplemented with 10% FBS, 2 mM sodium pyruvate (Sigma), and 1% penicillin/streptomycin solution. For transient transfections, the cells were cultured in phenol red-free medium supplemented with 10% charcoal-stripped FBS (Gemini-Bio) and seeded in 24-well plates at a density of 1.2 ϫ 10 5 cells/well (HepG2) and 0.8 ϫ 10 5 cells/ well (Balb3T3A31). The cells were transfected with the following DNA mixture for 6 h using Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions. For reporter assay, a DNA mixture contained 50 ng of expression plasmids for WT or mutated ER␣, 100 ng of reporter plasmids for 3xERE-TATA-luc or C3-110tk-luc, and 100 ng of pRL-TK was transfected in each well. For assessment of AF-2 activity, the DNA mixture contained 50 ng of expression plasmids for GAL4 DBD fusion proteins (pBIND), and 100 ng of pG5-Luc reporter plasmid was transfected in each well. pBIND plasmid contains Renilla luciferase expression unit for transfection normalization. For assessment of LBD dimerization, the DNA mixture contained 50 ng of expression plasmids for GAL4DBD fusion proteins (pBIND), 50 ng of expression plasmids for VP16 activation domain (AD) fusion proteins (pACT), and 100 ng of pG5-Luc reporter plasmid was transfected in each well. For assessment of coactivator interaction, the DNA mixture contained 100 ng of expression plasmids for GAL4DBD fused NCOA NR-box (pM), 50 ng of expression plasmids for VP16AD fusion proteins (pACT), 50 ng of pRL-TK, and 100 ng of pG5-Luc reporter plasmid was transfected in each well.
Luciferase assay
The cells were cultured in fresh medium supplemented with the ethanol as a vehicle and E2 (Steraloids) or 4OHT (Sigma) 6 h after transfections. Luciferase and Renilla luciferase activities were assayed 18 h after treatments using Dual-Luciferase Reporter Assay System (Promega). Luciferase activity was normalized for transfection efficiency using Renilla luciferase as an internal control. All results are representative of at least two independent experiments and represent the mean Ϯ S.D. of triplicate samples.
Western blotting assay
The transfected cells on 24-well plate were washed with PBS, and 100 l of 2ϫ Laemmli sample buffer (Bio-Rad) near 100°C was added to the wells. The cells were pipetted vigorously and then into a 1.5-ml centrifuge tube. The tubes were heated at 100°C for 10 min, cooled on ice, and stored at Ϫ80°C until the samples were analyzed on SDS-PAGE. Proteins were resolved by SDS-PAGE with 4 -12% gradient gel (Invitrogen) and subsequently transferred to nitrocellulose membrane. Blots were incubated overnight in 4°C with primary antibody for ER␣ (1:600; H-184, Santa Cruz Biotechnology) or ␤-actin (1:2000; AC-74, Sigma). The blots were washed and then incubated with IRDye 800CW-conjugated anti-rabbit antibody (LI-COR Biosciences) for ER␣ or with IRDye 680RD-conjugated anti-mouse antibody (LI-COR Bioscience) for ␤-actin. The signals were visualized by Odyssey IR imaging system (LI-COR Biosciences). BenchMark protein ladder (Invitrogen) was used for evaluating the molecular weight.
Condition for examining the ER␣-dependent endogenous gene expression
HeLa cells (human cervical cancer cell) were cultured in phenol red-free ␣-MEM supplemented with 10% FBS, 2 mM sodium pyruvate, and 1% penicillin/streptomycin solution. When the cells were transfected with DNAs, the cells were cultured in phenol red-free medium supplemented with 10% charcoal-stripped FBS and seeded into 6-well plates at a density of 4.5 ϫ 10 5 cells/well. The cells were transfected with the 2 g of pcDNA3-mERa, pcDNA3-hERa, or pcDNA3 for 6 h using Lipofectamine 2000. The cells were cultured with fresh phenol red-free medium supplemented with 10% charcoal-stripped FBS and ligand for 24 h. The cells were homogenized with TRIzol reagent (Invitrogen) for extracting RNA. Total RNA was treated with TURBO DNase (Invitrogen) and then reversetranscribed by Superscript II (Invitrogen) to generate the cDNA following the manufacturer's instruction. The quantitative PCR was performed by using the Fast SYBR Green Master Mix (Applied Biosystems) with cDNA and the gene-specific forward and reverse primers. The sequence of primers is listed as follows: hSERPINB9_F, 5Ј-TCT TTG GAG AGA AAA CTT GTC AGT-3Ј, and hSERPINB9_R, 5Ј-AAC AAC TCT TCA ATT TTA CCT TCG G-3Ј; pS2_F, 5Ј-CCC CGT GAA AGA CAG AAT TGT-3Ј, and pS2_R, 5Ј-GTC TAA AAT TCA CAC TCC TCT TCT GG-3Ј; h36B4_F, 5Ј-GGA CAT GTT GCT GGC CAA TAA-3Ј, and h36B4_R, 5Ј-GGG CCC GAG ACC AGT GTT-3Ј; Neo_5Ј, 5Ј-GGC TAT GAC TGG GCA CAA CAG ACA ATC-3Ј, and Neo_3Ј, 5Ј-TAC TTT CTC GGC AGG AGC AAG GTG AG-3Ј. The C t value was calculated by a mathematical model to quantify the relative mRNA level (22) . The level of Neo mRNA, which is expressed from the pcDNA3 plasmid, was analyzed for normalizing the transfection efficiency. The data were obtained from three independent experiments.
Statistical analysis
ANOVA with Tukey's multiple comparison test was performed by GraphPad Prism (GraphPad software). p Ͻ 0.05 was considered statistically significant. 
